Sun Pharma Licensed Global Cholesterol Drug Rights
Healthcare operators should track how this PCSK9 inhibitor's six-month ambient storage profile affects drug supply chains.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to prioritize patient accessibility when bringing new treatments to global markets?
Sun Pharmaceutical Industries entered a global licensing, commercialization, and manufacturing agreement with LIB Therapeutics for the cholesterol-lowering drug lerodalcibep. The drug is currently approved as Lyrokaul in the EU and Lerochol in the US to reduce LDL-C in adults.
Why it matters
The deal aims to capture share in the growing PCSK9 inhibitor market, which reached $3.7 billion outside the US and China as of Q2 2026, by addressing clinical needs for patients requiring higher LDL-C reductions.
The global PCSK9 inhibitor market reached $3.7 billion in the period ending Q2 2026, with Europe contributing $2.9 billion to that total. Sun Pharma stock ended the previous session at ₹1,855.9 per share.
The players
Sun Pharmaceutical Industries
A global specialty pharmaceutical company that manufactures and markets a broad range of generic and branded pharmaceutical products.
LIB Therapeutics
A biotechnology firm focused on the development of novel therapies for cardiovascular and metabolic diseases.
The details
Lerodalcibep is an antibody-mimetic biologic that inhibits PCSK9 and is administered via a 300 mg subcutaneous injection. The drug's formulation allows for six-month ambient storage, a logistical feature that simplifies distribution compared to traditional cold-chain biologics. Sun Pharma will manage manufacturing and commercialization duties globally to expand patient access.
Timeline
The PCSK9 inhibitor market reached $3.7 billion during Q2 2026.
Sun Pharma announced the licensing agreement on September 28, 2026.
Market Landscape
The partnership follows established clinical guidelines for LDL-C reduction that mandate intensive lipid management for high-risk cardiovascular patients. This move scales Sun Pharma's presence against the broader industry trend of prioritizing specialized biologics over standard statin-based therapies.
Operators in the pharmaceutical distribution and pharmacy space should monitor the logistics of the six-month ambient storage profile of lerodalcibep, as it may reduce operational cold-chain costs. Management should watch for regional regulatory shifts in LDL-C treatment standards to anticipate potential shifts in prescription volume.
The takeaway
This deal signals a competitive push to dominate the growing cardiovascular biologic sector by leveraging supply chain efficiencies. Healthcare operators should track the market uptake of shelf-stable biologics versus traditional cold-chain alternatives in the coming quarters.
Further reading
For more on industry shifts, visit the Healthcare section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient accessibility when bringing new treatments to global markets?
